PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 29 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
In silico molecular docking and dynamics simulations suggest that iridoid glycosides (loganin, secologanin, and loganetin) may inhibit GSK-3β, potentially improving memory and cognitive impairment [PMID:34692636].
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 39273607 (2024) — Evaluating the Dermatological Benefits of Snowberry (Symphoricarpos albus): A Comparative Analysis of Extracts and Fermented Products from Different Plant Parts. · International journal of molecular sciences
- 2.PMID: 501855 (1979) — Snowberry (Symphoricarpos) poisoning in children. · JAMA
- 3.PMID: 34692636 (2021) — Inhibition of GSK_3β by Iridoid Glycosides of Snowberry (Symphoricarpos albus) Effective in the Treatment of Alzheimer's Disease Using Computational Drug Design Methods. · Frontiers in chemistry
- 4.PMID: 12848374 (2003) — Phenolic acids from Symphoricarpos albus (L.) Blake (Caprifoliaceae). · Acta poloniae pharmaceutica
- 5.PMID: 30032925 (2018)